Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.67 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 4/20 | 0.61 |
| ▸ | CASP3 | P42574 | 1/20 | 0.61 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 1/20 | 0.54 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16628055 | 0.94 | RAF1 (0.63) | KDRTRPV1MEN1KMT2ACA1 | |
| SCHEMBL19668025 | 0.89 | MEN1 (0.61) | KDRMEN1KMT2AMAPTGAA | |
| SCHEMBL29145805 | 0.85 | KDR (0.53) | KDRTRPV1MEN1KMT2AMAPT | |
| SCHEMBL29145807 | 0.85 | KDR (0.53) | KDRTRPV1MEN1KMT2AMAPT | |
| SCHEMBL11007737 | 0.84 | MEN1 (0.61) | TRPV1MEN1KMT2AMAPTCASP3 | |
| SCHEMBL12310641 | 0.84 | KDR (0.76) | KDRTRPV1MEN1KMT2AMAPT | |
| SCHEMBL29145803 | 0.83 | KDR (0.54) | KDRTRPV1MEN1KMT2AMAPT | |
| SCHEMBL403261 | 0.83 | CA12 (0.51) | KDRMAPTCA1CA2CA7 | |
| SCHEMBL4118152 | 0.83 | LMNA (0.72) | KDRMEN1KMT2AMAPTCA1 | |
| SCHEMBL6014087 | 0.82 | CETP (0.52) | TRPV1MEN1KMT2AMAPTCASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2014-11-06 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841330-B2 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER HEALTHERCARE LLC (US) | 2012-06-07 | — | — | US | disclosed |
| EP-2298311-B1 | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER CORPORATION | 2002-04-11 | — | — | US | disclosed |
| EP-1158985-A1 | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | Bayer Corporation (US) | 2001-12-05 | — | — | EP | disclosed |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-25 | — | — | US | disclosed |
| EP-1140840-A1 | -G(V)-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | Bayer Corporation (US) | 2001-10-10 | — | — | EP | disclosed |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-10-04 | — | — | US | disclosed |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-23 | — | — | US | disclosed |
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BAYER HEALTHCARE LLC | 2001-08-02 | — | — | US | disclosed |
| WO-2000041698-A1 | φ-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
| WO-2000042012-A1 | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 2000-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011135-A1 | Omega-carboxyaryl subsituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 611/4885TRPV1 4576/4885MEN1 4453/4885 |
| US-20010011136-A1 | omega-carboxyyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, ARAF, RAF1 | KDR 624/4885TRPV1 4393/4885MEN1 4280/4885 |
| US-20010034447-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 567/4885TRPV1 4623/4885MEN1 4567/4885 |
| US-20010016659-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 567/4885TRPV1 4623/4885MEN1 4567/4885 |
| US-20140329866-A1 | OMEGA-CARBOXYARL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 456/4885TRPV1 4372/4885MEN1 4538/4885 |
| US-20010027202-A1 | Omega-carboxyaryl substituted disphenyl ureas as raf kinase inhibitors | BRAF, NRAS, ARAF | KDR 487/4885TRPV1 4458/4885MEN1 3519/4885 |
| US-20020042517-A1 | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors | BRAF, RAF1, ARAF | KDR 567/4885TRPV1 4623/4885MEN1 4567/4885 |
| US-20120142742-A1 | OMEGA-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | KDR 567/4885TRPV1 4623/4885MEN1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.